Delix Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$100M
- Investors
-
49
Delix Therapeutics General Information
Description
Developer of neuroplastogen therapeutics designed to treat neuropsychiatric and neurological conditions by promoting rapid and sustained neuroplasticity in targeted brain circuits. The company offers oral, non-hallucinogenic compounds that promote selective structural and functional neuroplasticity, enabling patients with difficult-to-treat brain disorders to access fast-acting, long-lasting treatments that can be administered outside clinical settings.
Contact Information
Website
www.delixtherapeutics.comCorporate Office
- 20 Authors Road
- Concord, MA 01742
- United States
Corporate Office
- 20 Authors Road
- Concord, MA 01742
- United States
Delix Therapeutics Timeline
Delix Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series C) | 09-Nov-2026 | $100M | Completed | Clinical Trials - Phase 2 | ||
| 8. Later Stage VC (Series B) | 15-Dec-2025 | Completed | Clinical Trials - Phase 2 | |||
| 7. Grant | 04-Jun-2024 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 01-Dec-2023 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series B) | 10-Jan-2022 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A) | 03-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 01-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 2. Corporate | 06-Mar-2020 | $500K | $500K | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Jan-2019 | Completed | Pre-Clinical Trials |
Delix Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Delix Therapeutics Comparisons
Industry
Financing
Details
Delix Therapeutics Competitors (12)
One of Delix Therapeutics’s 12 competitors is Intracellular Therapies, a Formerly VC-backed company based in Bedminster, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intracellular Therapies | Formerly VC-backed | Bedminster, NJ | ||||
| Gilgamesh Pharma | Venture Capital-Backed | New York, NY | ||||
| Neurocrine Biosciences | Formerly VC-backed | San Diego, CA | ||||
| MapLight Therapeutics | Formerly VC-backed | Burlington, MA | ||||
| Relmada Therapeutics | Formerly VC-backed | Coral Gables, FL |
Delix Therapeutics Patents
Delix Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026072561-A1 | Methods of using n-substituted indole neuroplastogens | Pending | 25-Sep-2024 | ||
| WO-2026072584-A1 | Methods of using phenoxy and benzyloxy substituted neuroplastogens | Pending | 25-Sep-2024 | ||
| WO-2026072510-A1 | Methods of identifying effective amounts of plastogens | Pending | 24-Sep-2024 | ||
| WO-2026035553-A1 | Patient specific methods of treating neuropsychiatric disorders with non-hallucinogenic tryptamines | Pending | 05-Aug-2024 | ||
| EP-4827835-A1 | Mixed serotonin receptor binders for treatment of psychotic disorders | Pending | 22-Dec-2023 | A61K45/06 |
Delix Therapeutics Signals
Delix Therapeutics Investors (49)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | ||
| Hamilton Square Partners Management | PE/Buyout | Minority | ||
| Johnson & Johnson JJDC | Corporate Venture Capital | Minority | ||
| SV Health Investors | PE/Buyout | Minority | ||
| Vestal Point Capital | Hedge Fund | Minority |
Delix Therapeutics FAQs
-
When was Delix Therapeutics founded?
Delix Therapeutics was founded in 2019.
-
Where is Delix Therapeutics headquartered?
Delix Therapeutics is headquartered in Concord, MA.
-
What is the size of Delix Therapeutics?
Delix Therapeutics has 24 total employees.
-
What industry is Delix Therapeutics in?
Delix Therapeutics’s primary industry is Drug Discovery.
-
Is Delix Therapeutics a private or public company?
Delix Therapeutics is a Private company.
-
What is Delix Therapeutics’s current revenue?
The current revenue for Delix Therapeutics is .
-
How much funding has Delix Therapeutics raised over time?
Delix Therapeutics has raised $208M.
-
Who are Delix Therapeutics’s investors?
Adage Capital Management, Hamilton Square Partners Management, Johnson & Johnson JJDC, SV Health Investors, and Vestal Point Capital are 5 of 49 investors who have invested in Delix Therapeutics.
-
Who are Delix Therapeutics’s competitors?
Intracellular Therapies, Gilgamesh Pharma, Neurocrine Biosciences, MapLight Therapeutics, and Relmada Therapeutics are some of the 12 competitors of Delix Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process